The CEO of Ilya Pharma, Evelina Vågesjö, is listed for Advanced therapies by the The Medicine Maker.
She is on the list together with the former Head of Cell- and Gene therapies at Novartis bringing the first CAR T cell therapy to market and the recent Nobel Laureates and users of the CRISPER technology.
The ILP-drug candidates and the lead candidate ILP100 developed in Topical and Oral formulations is indeed advanced therapy, it is a next generation immunotherapy and are developed to treat wounds in skin and mucosa, states Ilya Pharma.
The list is an annual celebration of the great and inspirational minds that contribute to the development and manufacture of new medicinal products, including small molecules, biopharmaceuticals, and advanced therapies.
Photo: Jenny Öhman